Gene Editing Market-Size, Share, Trends & Forecast 2030

Gene Editing Market Data Product Overview

The global Gene Editing Market data product covers market sizing, forecasts, segmentation, competitive benchmarking, and company profiles across product and services, gene editing technologies, approaches, delivery methods and modalities, therapies, modes, applications, end-users, and regions. Market figures are aggregated analyst estimates informed by primary expert interviews and secondary research from proprietary databases and industry journals. The market is projected to reach USD 17.79 billion by 2030, with a CAGR of 16.9% from 2025-2030. Geographic coverage includes North America, Europe, Asia-Pacific, and RoW, while the competitive landscape covers 15 companies.

Use Cases

• Market entry sizing: Assess the projected USD 17.79 billion market opportunity by 2030 and compare segment structures across technologies, applications, therapies, and end-users.

• Competitive benchmarking: Evaluate 15 profiled companies and their reported strategies, including collaborations and acquisitions, across the gene editing ecosystem.

• M&A target screening: Screen market participants across CRISPR, ZFN, gene therapy, genetic engineering, delivery modalities, and related service areas to support strategic transaction assessment.

• Vendor evaluation: Compare offerings and market positioning across reagents and consumables, systems and software, services, viral and non-viral vectors, and in-house versus contract modes.

Metadata

• Update Frequency: One-time syndicated

• Data Source(s): Primary interviews + secondary research (proprietary databases, industry journals)

• Original Publisher of data: Next Move Strategy Consulting

• Geographic coverage: North America, Europe, Asia-Pacific, and RoW

• Is historical data "point-in-time": Historical figures are point-in-time as of publication; forecast years are projections

• Data Set(s) Format(s): PDF / Excel

• Raw or scraped data: No syndicated analyst research

• Number of companies/brands covered: 15 Companies

Key Data Points

• Rising genetic disease: Increasing prevalence of genetic diseases such as sickle cell anemia and cystic fibrosis supports demand for gene editing treatments and genetic mutation correction.

• Growing agriculture sector: Demand for higher crop yields, disease resistance, and improved nutritional content is supporting investment in gene editing for plant genetic engineering.

• Advancement in CRISPR-Cas9: Improvements in CRISPR-Cas9 precision, efficiency, and affordability are supporting broader research, therapy development, and commercial innovation.

Pricing Information

Pricing is provided through the AWS Marketplace offer for this product. Tier-specific pricing, where applicable, is determined by the applicable AWS Marketplace offer.

Regulatory and Compliance Information

This report is built from aggregated, publicly available, and licensed secondary sources plus expert interviews conducted on an aggregated basis. It contains no individually identifiable personal data.

Subscription Verification

AWS Data Exchange requires subscription verification on all public offers (subscribers confirm they're not in a restricted country or a covered party).